# GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study

> **NCT03821129** · NA · RECRUITING · sponsor: **W.L.Gore & Associates** · enrollment: 636 (estimated)

## Conditions studied

- Stroke
- PFO - Patent Foramen Ovale

## Interventions

- **DEVICE:** PFO closure with GORE® CARDIOFORM Septal Occluder

## Key facts

- **NCT ID:** NCT03821129
- **Lead sponsor:** W.L.Gore & Associates
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-07-25
- **Primary completion:** 2028-10
- **Final completion:** 2031-10
- **Target enrollment:** 636 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03821129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03821129, "GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT03821129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*